Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

Part of paid clinical trials in San Diego, California.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT03945903
Status
No Longer Available

Conditions

Eligibility Criteria

Sex
All
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Golimumab — DRUG
    Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.

Study Details

This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults. The main purpose of a single patient IND is to provide treatment to participants with serious/life-threatening diseases or conditions prior to marketing authorization.

Key Dates

Status verified
Apr 2023

Locations (1)

FacilityCityStateZIPSite coordinators
Rady Children's HospitalSan DiegoCalifornia92123-

Find similar trials in San Diego, CA

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
Rady Children's Hospital· San Diego, CA

Related Studies